Current Challenges and Developments in Managing Patients with Glanzmann Thrombasthenia

Click the “Start Program” button to indicate you have reviewed the CME/CE information for this activity.
Start Program


Release Date: April 9, 2019
Expiration Date: April 9, 2020
Estimated Time to Complete Activity: 45 minutes
Minimum System Requirements:
  • Internet Explorer 10 (or higher)
  • Mozilla Firefox 48 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 15.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)

Target Audience
This on-line CME activity is designed to meet the educational needs of hemophilia HEM/ONCs, hemophilia specialists, critical care specialists and other hospitalists, APRNs, nurse coordinators, nurse practitioners, staff nurses, hematology laboratorians, and other HCPs who manage and counsel persons with Glanzmann thrombasthenia and their families/caregivers.

Statement of Need/Program Overview
Glanzmann thrombasthenia (GT) is a rare inherited platelet disorder that is characterized by spontaneous or postprocedural bleeding. Diagnoses can be challenging because of the similarity in bleeding patterns across a variety of platelet disorders and the absence of diagnostic indicators revealed through initial laboratory assessments. Thus, its diagnosis depends on identifying the dysfunction of the platelets; and, although inherited through recessive inheritance, a strong family history helps in the diagnosis as carriers of the disease may be concentrated in communities with a tradition of consanguinity.

Hence, there is a need to educate both clinicians and their patients/caregivers about the diagnosis of GT, as well as new and emerging data about it's treatment, and to exchange experiences and perspectives with an expert on the management of the disease.

Educational Objectives
After participating in this activity, the participant should be better able to:

  • Review the pathogenesis, laboratory findings, and clinical presentation of Glanzmann thrombasthenia.
  • Discuss current challenges in the laboratory evaluation and clinical diagnosis of Glanzmann thrombasthenia.
  • Assess clinical data and expert opinion on the management of platelet transfusions and the risk of developing platelet refractoriness in patients with Glanzmann thrombasthenia.
  • Evaluate management strategies, therapeutic options and assessments, and patient/caregiver education tools for persons with Glanzmann thrombasthenia.

Presenting Faculty
Meera B. Chitlur, MD
Meera B. Chitlur, MD
Barnhart-Lusher Hemostasis Research Endowed Chair
Director, Hemophilia Treatment Center and Hemostasis Program
& Special Coagulation Laboratory
Professor of Pediatrics, Wayne State University
Division of Hematology/Oncology
Children's Hospital of Michigan
Detroit, MI

Joint Accreditation Statement

accredited

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Educational Concepts in Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

ASCLS P.A.C.E.® Credits
Postgraduate Institute for Medicine is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. This program is approved for up to 1.0 ASCLS P.A.C.E.® contact hours.  

Interprofessional Continuing Education

ipce

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

PA Continuing Education
PAs may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Method of Participation
During the period of  April 9, 2019, through April 9, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question
  • Complete the evaluation form

A statement of credit will be issued automatically upon successful completion of the post-activity survey with a score of 75% or better and submitting the activity evaluation.

Fee Information
There is no fee for this educational activity.

Disclosure of Conflicts of Interest
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Meera B. Chitlur, MD Consulting Fees: Novo Nordisk, Octapharma, and Shire/Takeda

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Postgraduate Institute for Medicine Clinical Reviewers Have no real or apparent conflicts of interest to report.
Educational Concepts in Medicine Reviewers Have no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Media
Internet

Commercial Support
This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc.

This activity is jointly provided by:

support